Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 1:22 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 307 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: NASH - Nonalcoholic Steatohepatitis; NAFLD - Nonalcoholic Fatty Liver Disease Clear all
Recruiting Phase 2 Interventional

A Phase 2a Study of ALN-PNP With and Without a GLP1R Agonist in Adult Patients With Homozygous PNPLA3-Related MASLD

NCT07527910
View directory record Official record
Conditions
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Interventions
ALN-PNP, Tirzepatide, Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
204 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
9
States / cities
Tucson, Arizona • Coronado, California • Pasadena, California + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 22, 2026, 1:22 PM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Bariatric Embolization of Arteries for the Treatment of Nonalcoholic Steatohepatitis

NCT02933554
View directory record Official record
Conditions
Obesity, Weight Loss, Body Weight, Nonalcoholic Steatohepatitis, Nonalcoholic Fatty Liver Disease, NAFLD
Interventions
Embospheres Microspheres
Device
Lead sponsor
Keith Pereira, MD:
Other
Eligibility
22 Years to 65 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 28, 2025 · Synced Oct 22, 2026, 1:22 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Pharmacokinetics and Pharmacodynamics of Cilofexor in Adults With Normal and Impaired Hepatic Function

NCT02808312
View directory record Official record
Conditions
Nonalcoholic Steatohepatitis (NASH), Primary Sclerosing Cholangitis (PSC)
Interventions
Cilofexor
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
4
States / cities
Miami, Florida • Orlando, Florida • Knoxville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 7, 2021 · Synced Oct 22, 2026, 1:22 PM EDT
Completed Phase 3 Interventional

Development of a Breath Test for Monitoring Patients With Liver Disease

NCT00244569
View directory record Official record
Conditions
Fatty Liver, Cirrhosis
Interventions
13C-Methacetin, Breath ID Machine
Drug · Device
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 20, 2017 · Synced Oct 22, 2026, 1:22 PM EDT
Terminated Phase 2 Interventional Results available

Study of Various Treatments in Non-alcoholic Fatty Liver Disease (NAFLD) Patients Who Have Aspects of Non-alcoholic Steatohepatitis (NASH)

NCT04147195
View directory record Official record
Conditions
Non-alcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis
Interventions
LYS006, Tropifexor
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
8
States / cities
Coronado, California • Los Angeles, California • Miami Lakes, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2023 · Synced Oct 22, 2026, 1:22 PM EDT
Terminated Phase 2 Interventional Results available

Rollover Study of Cenicriviroc for the Treatment of Liver Fibrosis in Participants With Nonalcoholic Steatohepatitis

NCT03059446
View directory record Official record
Conditions
Nonalcoholic Steatohepatitis, Liver Cirrhosis, Non-alcoholic Fatty Liver Disease
Interventions
Cenicriviroc
Drug
Lead sponsor
Tobira Therapeutics, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
167 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
41
States / cities
Dothan, Alabama • Phoenix, Arizona • Tucson, Arizona + 36 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2022 · Synced Oct 22, 2026, 1:22 PM EDT
Active, not recruiting Phase 2 Interventional

Statins for the Treatment of NASH

NCT04679376
View directory record Official record
Conditions
NASH - Nonalcoholic Steatohepatitis
Interventions
Atorvastatin, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 70 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
2
States / cities
Rochester, Minnesota • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 20, 2026 · Synced Oct 22, 2026, 1:22 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase 1 Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Multiple Oral Doses of MGL-3196 in Subjects With Varying Degrees of Hepatic Impairment and Healthy Matched Control Subjects

NCT04643795
View directory record Official record
Conditions
Hepatic Impairment, NASH - Nonalcoholic Steatohepatitis, Cirrhosis, Liver
Interventions
MGL-3196
Drug
Lead sponsor
Madrigal Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
87 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
3
States / cities
Orlando, Florida • Saint Paul, Minnesota • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 5, 2023 · Synced Oct 22, 2026, 1:22 PM EDT
Completed Not applicable Interventional Results available

Fish Oil and Nonalcoholic Fatty Liver Disease (NAFLD) Study

NCT01285362
View directory record Official record
Conditions
Non-Alcoholic Fatty Liver Disease
Interventions
Fish Oil Supplementation, Placebo Supplementation
Drug
Lead sponsor
Columbia University
Other
Eligibility
12 Years to 18 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 5, 2022 · Synced Oct 22, 2026, 1:22 PM EDT
Completed Phase 2 Interventional Results available

LIFT Study: A Safety, Tolerability, Efficacy, and Pharmacokinetics Study of TERN-101 in Subjects With Non-Cirrhotic Non-Alcoholic Steatohepatitis (NASH)

NCT04328077
View directory record Official record
Conditions
NASH - Nonalcoholic Steatohepatitis
Interventions
TERN-101, Placebo
Drug · Other
Lead sponsor
Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years to 75 Years
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
31
States / cities
Chandler, Arizona • Tucson, Arizona • Coronado, California + 23 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2022 · Synced Oct 22, 2026, 1:22 PM EDT
Withdrawn Phase 1 Interventional

A Study of BMN 255 in Participants With Non-Alcoholic Fatty Liver Disease And Hyperoxaluria

NCT06138327
View directory record Official record
Conditions
Hyperoxaluria, Nonalcoholic Fatty Liver Disease, Kidney Stone
Interventions
BMN 255, Placebo
Drug
Lead sponsor
BioMarin Pharmaceutical
Industry
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
7
States / cities
Birmingham, Alabama • Chula Vista, California • Chula Vista Isles, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2024 · Synced Oct 22, 2026, 1:22 PM EDT
Completed Phase 2 Interventional Results available

Clinical Trial to Evaluate Efficacy of GR-MD-02 for Treatment of Liver Fibrosis in Patients With NASH With Advanced Fibrosis

NCT02421094
View directory record Official record
Conditions
Nonalcoholic Steatohepatitis
Interventions
GR-MD-02, Placebo
Drug
Lead sponsor
Galectin Therapeutics Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Fort Sam Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 8, 2020 · Synced Oct 22, 2026, 1:22 PM EDT
Completed Not applicable Interventional

Diabetes Prevention Program for the Treatment of Nonalcoholic Fatty Liver Disease

NCT04988204
View directory record Official record
Conditions
Nonalcoholic Fatty Liver Disease
Interventions
Diabetes Prevention Program
Behavioral
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 3, 2021 · Synced Oct 22, 2026, 1:22 PM EDT
Terminated Phase 3 Interventional Results available

Eltrombopag To Reduce The Need For Platelet Transfusion In Subjects With Chronic Liver Disease And Thrombocytopenia Undergoing Elective Invasive Procedures

NCT00678587
View directory record Official record
Conditions
Non-alcoholic Steatohepatitis, Chronic Liver Disease, HCV, NASH - Nonalcoholic Steatohepatitis, HIV Infection, Thrombocytopenia, Hepatitis C Virus, HBV, Human Immunodeficiency Virus, Liver Diseases, Hepatitis B Virus
Interventions
Eltrombopag, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
292 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
33
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 28 more
Source: ClinicalTrials.gov public record
Updated Oct 12, 2018 · Synced Oct 22, 2026, 1:22 PM EDT
Completed Not applicable Interventional Results available

Effects of Pitavastatin on Insulin Sensitivity and Liver Fat

NCT02290106
View directory record Official record
Conditions
Obesity, Fatty Liver, Nonalcoholic
Interventions
pitavastatin, PLACEBO
Drug · Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
40 Years to 65 Years · Male only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 2, 2019 · Synced Oct 22, 2026, 1:22 PM EDT
Completed Not applicable Interventional

Exercise Versus Diet in the Treatment of Nonalcoholic Fatty Liver Disease

NCT01327443
View directory record Official record
Conditions
Non Alcoholic Fatty Liver Disease
Interventions
Weight loss, Exercise
Behavioral
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
18 Years to 60 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 5, 2016 · Synced Oct 22, 2026, 1:22 PM EDT
Withdrawn Not applicable Interventional

A Study to See if Low Level Laser Light Therapy (LLLT) Can Improve the Condition of Nonalcoholic Steatohepatitis (NASH)

NCT03163810
View directory record Official record
Conditions
Nonalcoholic Steatohepatitis
Interventions
Erchonia Verju Laser, Erchonia EVRL Laser
Device
Lead sponsor
Erchonia Corporation
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Jan 28, 2020 · Synced Oct 22, 2026, 1:22 PM EDT
Completed Phase 2 Interventional Results available

A Study of the Safety and Tolerability of LPCN 1144 in Subjects Who Completed the LPCN 1144-18-002 Trial

NCT04685993
View directory record Official record
Conditions
NASH - Nonalcoholic Steatohepatitis
Interventions
LPCN 1144
Drug
Lead sponsor
Lipocine Inc.
Industry
Eligibility
18 Years to 80 Years · Male only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
10
States / cities
Roseville, California • Ocoee, Florida • Las Vegas, Nevada + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2024 · Synced Oct 22, 2026, 1:22 PM EDT
Completed Phase 2 Interventional

PK of NRL972 in Patients with Nonalcoholic Steatohepatitis (NASH) and Non-Alcoholic Fatty Liver Disease (NAFLD)

NCT00794716
View directory record Official record
Conditions
Non-Alcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis
Interventions
NRL972
Drug
Lead sponsor
Norgine
Industry
Eligibility
18 Years to 80 Years
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 22, 2026, 1:22 PM EDT
Completed Phase 2 Interventional Results available

Study of Pharmacodynamics and Safety of DGAT2i and ACCi Coadministered in Participants With Sponsor-defined Presumed Non Alcoholic Steatohepatitis

NCT04399538
View directory record Official record
Conditions
Nonalcoholic Steatohepatitis, Nonalcoholic Fatty Liver Disease
Interventions
PF-06865571, PF-05221304, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 75 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
11
States / cities
Lincoln, California • Montclair, California • Boca Raton, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2023 · Synced Oct 22, 2026, 1:22 PM EDT
Completed Not applicable Interventional Results available

Dietary Treatment Study of Pediatric NAFLD

NCT02513121
View directory record Official record
Conditions
Nonalcoholic Fatty Liver Disease
Interventions
Dietary modification
Other
Lead sponsor
University of California, San Diego
Other
Eligibility
11 Years to 16 Years · Male only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
2
States / cities
San Diego, California • Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jan 28, 2020 · Synced Oct 22, 2026, 1:22 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Drug-drug Interaction Study to Investigate the Effect of Coadministration of EDP-305 on the PK of a Combined Oral Contraceptive in Healthy Female Subjects

NCT03783897
View directory record Official record
Conditions
NASH - Nonalcoholic Steatohepatitis
Interventions
EDP-305, Oral Contraceptive
Drug
Lead sponsor
Enanta Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 24, 2019 · Synced Oct 22, 2026, 1:22 PM EDT
Completed Phase 2 Interventional Results available

A Study of IDN-6556 in Subjects With NAFLD and Raised Transaminases

NCT02077374
View directory record Official record
Conditions
Nonalcoholic Steatohepatitis, Non-alcoholic Fatty Liver Disease
Interventions
IDN-6556, Placebo
Drug · Other
Lead sponsor
Conatus Pharmaceuticals Inc.
Industry
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
7
States / cities
Miami, Florida • Indianapolis, Indiana • Detroit, Michigan + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 30, 2016 · Synced Oct 22, 2026, 1:22 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Multiple Ascending Dose Study of HU6 in High BMI Volunteers

NCT04709913
View directory record Official record
Conditions
NASH - Nonalcoholic Steatohepatitis
Interventions
HU6
Drug
Lead sponsor
Rivus Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 16, 2021 · Synced Oct 22, 2026, 1:22 PM EDT